Table S2.
Sensitivity analysis results
| Variables | Total cost – net treatments (thousands of €)
|
Total cost – gross treatments(thousands of €)
|
||||
|---|---|---|---|---|---|---|
| Mean values | Min values | Max values | Mean values | Min values | Max values | |
| Base case | 202,924.5 | 196,544.4 | 210,895.6 | 220,051.8 | 213,671.7 | 228,022.9 |
| Abiraterone (+10%) | 206,524.9 | 200,215.0 | 214,421.9 | 225,361.2 | 219,051.3 | 233,258.3 |
| Abiraterone (−10%) | 199,280.7 | 192,831.3 | 207,325.0 | 214,689.0 | 208,239.6 | 222,733.2 |
| Cabazitaxel (+10%) | 203,024.2 | 196,637.7 | 210,999.0 | 220,108.6 | 213,722.2 | 228,083.4 |
| Cabazitaxel (−10%) | 202,854.4 | 196,479.5 | 210,823.5 | 220,024.6 | 213,649.6 | 227,993.7 |
| Docetaxel (+10%) | 196,132.9 | 189,682.9 | 204,140.0 | 212,261.6 | 205,811.6 | 220,268.7 |
| Docetaxel (−10%) | 209,731.8 | 203,420.0 | 217,669.3 | 227,847.8 | 221,535.9 | 235,785.3 |
| Enzalutamide (+10%) | 204,933.0 | 198,537.9 | 212,952.6 | 221,680.8 | 215,285.7 | 229,700.3 |
| Enzalutamide (−10%) | 200,923.6 | 194,557.4 | 208,847.6 | 218,420.5 | 212,054.4 | 226,344.5 |
| Radium-223 (+10%) | 203,087.7 | 196,724.1 | 211,041.9 | 219,963.0 | 213,599.4 | 227,917.2 |
| Radium-223 (−10%) | 202,722.6 | 196,325.5 | 210,711.1 | 220,091.9 | 213,694.9 | 228,080.5 |
| Patients treated in first-line (+10%) | 217,054.9 | 210,238.7 | 225,574.0 | 235,535.4 | 228,719.2 | 244,054.6 |
| Patients treated in first-line (−10%) | 188,782.5 | 182,838.2 | 196,206.3 | 204,550.0 | 198,605.6 | 211,973.7 |
| Patients treated in second-line (+10%) | 209,118.2 | 202,534.6 | 217,340.4 | 226,601.3 | 220,017.8 | 234,823.6 |
| Patients treated in second-line (−10%) | 196,736.8 | 190,559.4 | 204,457.7 | 213,504.9 | 207,327.5 | 221,225.8 |
| Patients treated with external beam radiotherapy (+100%) | 205,549.8 | 199,169.7 | 213,520.9 | 222,677.1 | 216,297.0 | 230,648.2 |
| Patients treated with denosumab (+100%) | 203,739.3 | 197,359.2 | 211,710.4 | 220,866.6 | 214,486.5 | 228,837.7 |
| Patients treated with zoledronic acid (+10%) | 203,452.5 | 197,072.4 | 211,423.6 | 220,579.8 | 214,199.7 | 228,550.9 |
| Patients treated with zoledronic acid (−10%) | 202,396.5 | 196,016.5 | 210,367.6 | 219,523.8 | 213,143.8 | 227,494.9 |
| Patients treated with ADT (−10%) | 201,322.5 | 195,432.6 | 208,653.3 | 218,449.8 | 212,559.9 | 225,780.6 |
Abbreviations: min, minimum; max, maximum; ADT, androgen deprivation therapy.